Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL

Tumor Biology

Volumn 36, Issue 7, 2015, Pages 4913-4921

  Chen, Yang ^a   Shen, Zuojun ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

ALL; Gene polymorphism; MTX; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CYCLIN D1; DIHYDROFOLATE REDUCTASE; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; METHOTREXATE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 1; REDUCED FOLATE CARRIER; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; THYMIDYLATE SYNTHASE; FOLIC ACID; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ANEMIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CCND1 GENE; DHFR GENE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; FOLATE METABOLISM; FPGS GENE; GASTROINTESTINAL TOXICITY; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GGH GENE; HUMAN; LEUKOPENIA; LIVER TOXICITY; META ANALYSIS (TOPIC); MTHFR GENE; MTR GENE; MTRR GENE; NEPHROTOXICITY; ORAL MUCOSITIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RFC1 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; SLCO1B1 GENE; STOMATITIS; THROMBOCYTOPENIA; TS GENE; ADVERSE DRUG REACTION; GENETICS; METABOLISM; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLIC ACID; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHOTREXATE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

EID: 84938214644     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3602-0     Document Type: Review

References (84)

1. Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr Opin Pediatr. 2007;19:15–22.
2. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36:277–85.
3. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–78.
4. Kodidela S, Suresh Chandra P, Dubashi B. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur J Clin Pharmacol. 2014;70:253–60.
5. Kapoor G, Sinha R, Abedin S. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer. 2012;59:448–53.
6. Salazar J, Altés A, del Río E, et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates even-free survival in childhood acute lympho-blastic leukaemia. Pharmacogenomics J. 2012;12:379–85.
7. Niedzielska E, Węcławek-Tompol J, Matkowska-Kocjan A, et al. The influence of genetic RFC1, MS and MTHFR polymorphisms on the risk of acute lymphoblastic leukemia relapse in children and the adverse effects of methotrexate. Adv Clin Exp Med. 2013;22:579–84.
8. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer. 2006;6:117–29.
9. Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013;121:5145–53.
10. McGuire JJ, Bertino JR. Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem. 1981;38(Spec No(Pt 1)):19–48.
11. Organista-Nava J, Gómez-Gómez Y, Saavedra-Herrera MV, et al. Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. Leuk Res. 2010;34:728–32.
12. Garcia-Bournissen F, Moghrabi A, Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leuk Res. 2007;31:1023–5.
13. Wang L, Goodey NM, Benkovic SJ, et al. Coordinated effects of distal mutations on environmentally coupled tunneling in dihydrofolate reductase. Proc Natl Acad Sci U S A. 2006;103:15753–8.
14. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics. 2004;5:819–34.
15. Bagley PJ, Selhub J. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci U S A. 1998;95:13217–20.
16. Ansari M, St-Onge G, Krajinovic M. Pharmacogenomics of acute lymphoblastic leukemia. Med Sci (Paris). 2007;23:961–7.
17. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146:489–503.
18. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183–201.
19. Chiabai MA, Lins TC, Pogue R, et al. Population analysis of pharmacogenetic polymorphisms related to acute lymphoblastic leukemia drug treatment. Dis Markers. 2012;32:247–53.
20. Chiusolo P, Giammarco S, Bellesi S, et al. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. Cancer Chemother Pharmacol. 2012;69:691–6.
21. Gregers J, Christensen IJ, Dalhoff K, et al. The association of reduced folate carrier 80G > A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010;115:4671–7.
22. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007;109:4151–7.
23. He HR, Liu P, He GH, et al. Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Lymphoma. 2014;55:2793–800.
24. de Jonge R, Hooijberg JH, van Zelst BD, et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood. 2005;106:717–20.
25. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105:4752–8.
26. Huang L, Tissing WJ, de Jonge R, et al. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia. 2008;22:1798–800.
27. Kishi S, Griener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084–91.
28. Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, et al. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007;86:609–11.
29. Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30:347–52.
30. Faganel Kotnik B, Grabnar I, Bohanec Grabar P, et al. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 2011;67:993–1006.
31. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006;28:64–8.
32. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52:166–71.
33. Zhang HN, He XL, Wang C, et al. Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate. Pediatr Blood Cancer. 2014;61:2203–7.
34. Trevin˜o LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009;27:5972–8.
35. Zhang H, He X, Li J, et al. SLCO1B1c. 521T > C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi. 2014;52:770–6. Chinese.
36. Lopez-Lopez E, Ballesteros J, Piñan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia. Pharmacogenet Genomics. 2013;23:53–61.
37. Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;57:612–9.
38. Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 2013;121:898–904.
39. Liu Y, Yin Y, Sheng Q, et al. Association of ABCC2 -24C > T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One. 2014;9, e82681.
40. Rau T, Erney B, Göres R, et al. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther. 2006;80:468–76.
41. Sharifi MJ, Bahoush G, Zaker F, et al. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31:169–77.
42. El Mesallamy HO, Rashed WM, Hamdy NM, et al. High-dose methotrexate in Egyptian pediatric acute lymphoblastic leukemia: the impact of ABCG2 C421A genetic polymorphism on plasma levels, what is next? J Cancer Res Clin Oncol. 2014;140:1359–65.
43. Ansari M, Sauty G, Labuda M, et al. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2012;12:386–94.
44. Ansari M, Sauty G, Labuda M, et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood. 2009;114:1383–6.
45. Suthandiram S, Gan GG, Zain SM, et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014;15:1479–94.
46. Liani E, Rothem L, Bunni MA, et al. Loss of folylpolygamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003;103:587–99.
47. Liu SG, Gao C, Li ZG, et al. Correlation analysis of FPGS rs10760502G > a polymorphism with prognosis and MTX-related toxicity in pediatric B-cell acute lymphoblastic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22:291–7. doi:10.7534/j.issn.1009-2137. 2014.02.006. Chinese.
48. Liu SG, Gao C, Zhang RD, et al. FPGS rs1544105 polymorphism is associated with treatment outcome in pediatric B-cell precursor acute lymphoblastic leukemia. Cancer Cell Int. 2013;13:107.
49. Koomdee N, Hongeng S, Apibal S, et al. Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2012;13:3461–4.
50. Chen X, Wen F, Yue L, et al. Genetic polymorphism of γ-glutamyl hydrolase in Chinese acute leukemia children and identification of a novel double nonsynonymous mutation. Pediatr Hematol Oncol. 2012;29:303–12.
51. Xu X, Gammon MD, Wetmur JG, et al. A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. Am J Clin Nutr. 2007;85:1098–102.
52. Gómez-Gómez Y, Organista-Nava J, Saavedra-Herrera MV, et al. Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms. Exp Ther Med. 2012;3:665–72.
53. Ongaro A, De Mattei M, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94:1391–8.
54. Danenberg PV. Thymidylate synthetase—a target enzyme in cancer chemotherapy. Biochim Biophys Acta. 1977;473:73–92.
55. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5’ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res. 2003;63:2898–904.
56. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood. 2002;99:3786–91.
57. Erčulj N, Kotnik BF, Debeljak M, et al. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53:1096–104.
58. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2004;4:66–72.
59. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A. 1999;96:12810–5.
60. Narayanan S, McConnell J, Little J, et al. Associations between two common variants C677T and A1298C in the methylenetetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strand breaks, misincorporated uracil, and DNA methylation status) in human lymphocytes in vivo. Cancer Epidemiol Biomarkers Prev. 2004;13:1436–43.
61. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.
62. Haase R, Elsner K, Merkel N, et al. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C > T and 1298A > C polymorphisms on MTX-related toxicity. Klin Padiatr. 2012;224:156–9.
63. EL-Khodary NM, El-Haggar SM, Eid MA, et al. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol. 2012;29:2053–62.
64. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13:1915–8.
65. Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol. 2012;33:1445–54.
66. Ruiz-Argüelles GJ, Coconi-Linares LN, Garcés-Eisele J, et al. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico. Hematology. 2007;12:387–91.
67. Krull KR, Brouwers P, Jain N, et al. Folate pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr. 2008;152:101–5.
68. Liu JX, Chen JP, Tan W, et al. Association between mthfr gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008;16:488–92. Chinese.
69. Tantawy AA, El-Bostany EA, Adly AA, et al. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2010;21:28–34.
70. Karathanasis NV, Stiakaki E, Goulielmos GN, et al. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers. 2011;15:5–10.
71. Liu SG, Li ZG, Cui L, et al. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leuk Lymphoma. 2011;52:1030–40.
72. D'Angelo V, Ramaglia M, Iannotta A, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol. 2011;68:1339–46.
73. Li TY, Wang B, Xu KK, et al. Polymorphism C677T in methylenetetrahydrofolate reductase gene and its relationship to methotrexate-induced toxicities of childhood acute lymphoblastic leukemia. Acta Univ Med Nanjing (Nat Sci). 2010;30:386-9–404. Chinese.
74. Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res. 2007;31:1669–74.
75. Ayad MW, El Naggar AA, El Naggar M. MTHFR C677T polymorphism: association with lymphoid neoplasm and effect on methotrexate therapy. Eur J Haematol. 2014;93:63–9.
76. Seidemann K, Book M, Zimmermann M, et al. MTHFR 677 (C– > T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol. 2006;85:291–300.
77. Liao QC, Li XL, Liu ST, et al. Association between the methylenetetrahydrofolate reductase gene polymorphisms and haplotype with toxicity response of high dose methotrexate chemotherapy. Zhonghua Liu Xing Bing Xue Za Zhi. 2012;33:735–9. Chinese.
78. Hum DW, Bell AW, Rozen R, et al. Primary structure of a human trifunctional enzyme. Isolation of a cDNA encoding methylenetetrahydrofolate dehydrogenase-methenyltetrahydrofolate cyclohydrolase-formyltetrahydrofolate synthetase. J Biol Chem. 1988;263:15946–50.
79. Hol FA, van der Put NM, Geurds MP, et al. Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects. Clin Genet. 1998;53:119–25.
80. Leclerc D, Campeau E, Goyette P, et al. A. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet. 1996;5:1867–74.
81. Brown CA, McKinney KQ, Kaufman JS, et al. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk. 2000;7:197–200.
82. Costea I, Moghrabi A, Krajinovic M. The influence of cyclin D1 (CCND1) 870A > G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2003;13:577–80.
83. Hosokawa Y, Tu T, Tahara H, et al. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett. 1995;93:165–70.
84. Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica. 2006;91:1113–6.